Related references
Note: Only part of the references are listed.Molecular mechanisms underlying rheumatoid arthritis and cancer development and treatment
Susan Morand et al.
FUTURE ONCOLOGY (2020)
The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication
Madalena Tarsounas et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2020)
An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers
Ewa Przybytkowski et al.
BMC CANCER (2020)
TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials
Khalil Choucair et al.
CANCER GENE THERAPY (2020)
Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer.
Ursula A. Matulonis et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Molecular Trajectory of BRCA1 and BRCA2 Mutations
Yuichiro Hatano et al.
FRONTIERS IN ONCOLOGY (2020)
Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance
Stephen J. Pettitt et al.
CANCER DISCOVERY (2020)
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
Rodney P Rocconi et al.
LANCET ONCOLOGY (2020)
Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance
Johnathan Oh et al.
GYNECOLOGIC ONCOLOGY REPORTS (2020)
Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer
Adam A. Kraya et al.
CLINICAL CANCER RESEARCH (2019)
Genomic correlates of response to immune checkpoint blockade
Tanya E. Keenan et al.
NATURE MEDICINE (2019)
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer Phase 1b Results From the JAVELIN Solid Tumor Trial
Mary L. Disis et al.
JAMA ONCOLOGY (2019)
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
U. A. Matulonis et al.
ANNALS OF ONCOLOGY (2019)
N6-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance
Takeshi Fukumoto et al.
CANCER RESEARCH (2019)
Association of BRCA1-and BRCA2-deficiency with mutation burden, expression of PD-L1/ PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer
Wei Xiong Wen et al.
PLOS ONE (2019)
BARD1 is a Low/Moderate Breast Cancer Risk Gene: Evidence Based on an Association Study of the Central European p.Q564X Recurrent Mutation
Malwina Suszynska et al.
CANCERS (2019)
Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial
E. Pujade-Lauraine et al.
GYNECOLOGIC ONCOLOGY (2019)
1412PAnalytical performance of the resolution-HRD plasma assay used to identify mCRPC patients with biallelic disruption of DNA repair genes for treatment with niraparib
I Pekker et al.
ANNALS OF ONCOLOGY (2019)
The multifaceted role of autophagy in cancer and the microenvironment
Hendrik Folkerts et al.
MEDICINAL RESEARCH REVIEWS (2019)
PALB2 connects BRCA1 and BRCA2 in the G2/M checkpoint response
Srilatha Simhadri et al.
ONCOGENE (2019)
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Kevin K. Lin et al.
CANCER DISCOVERY (2019)
Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer
Nana Weber-Lassalle et al.
BREAST CANCER RESEARCH (2019)
Acetylation of 53BP1 dictates the DNA double strand break repair pathway
Xiang Guo et al.
NUCLEIC ACIDS RESEARCH (2018)
Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma
Ying Dai et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis
Yong-Wen Huang
MEDICINE (2018)
Role of BRCA Mutations in the Modulation of Response to Platinum Therapy
Sanghamitra Mylavarapu et al.
FRONTIERS IN ONCOLOGY (2018)
The interplay between exosomes and autophagy - partners in crime
Jing Xu et al.
JOURNAL OF CELL SCIENCE (2018)
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
Olga Kondrashova et al.
NATURE COMMUNICATIONS (2018)
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
Darren R. Hodgson et al.
BRITISH JOURNAL OF CANCER (2018)
Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
Isabella Faraoni et al.
CANCERS (2018)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
The crosstalk between autophagic and endo-/exosomal pathways in antigen processing for MHC presentation in anticancer T cell immune responses
Liangshun You et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation
Beatrice Rondinelli et al.
NATURE CELL BIOLOGY (2017)
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Olga Kondrashova et al.
CANCER DISCOVERY (2017)
The Role of Genetic Testing in Patients With Breast Cancer A Review
Olivia M. Valencia et al.
JAMA SURGERY (2017)
ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
Aparajitha Vaidyanathan et al.
BRITISH JOURNAL OF CANCER (2016)
New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors
Fong W. Liu et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2016)
Homologous recombination deficiency and ovarian cancer
Jonathan A. Ledermann et al.
EUROPEAN JOURNAL OF CANCER (2016)
BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study
Philipp Harter et al.
GYNECOLOGIC ONCOLOGY (2016)
Phase II study of Vigil DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer
Jonathan Oh et al.
GYNECOLOGIC ONCOLOGY (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
Kyle C. Strickland et al.
ONCOTARGET (2016)
FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair
Zeina Kais et al.
CELL REPORTS (2016)
Poly-ADP-ribosylation signaling during DNA damage repair
Barbara Golia et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2015)
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Panagiotis A. Konstantinopoulos et al.
CANCER DISCOVERY (2015)
Cancers Associated With BRCA1 and BRCA2 Mutations Other Than Breast and Ovarian
Jacqueline Mersch et al.
CANCER (2015)
BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance
Janneke E. Jaspers et al.
CANCER RESEARCH (2015)
The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers
Helen Cavanagh et al.
HEREDITARY CANCER IN CLINICAL PRACTICE (2015)
VEGFR3 Inhibition Chemosensitizes Ovarian Cancer Stemlike Cells through Down-Regulation of BRCA1 and BRCA2
Jaeyoung J. Lim et al.
NEOPLASIA (2014)
Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer
K. Danza et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2013)
Touching base with PARPs: moonlighting in the repair of UV lesions and double-strand breaks
Alex Pines et al.
TRENDS IN BIOCHEMICAL SCIENCES (2013)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
Phase I Trial of bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell Vaccine (FANG) in Advanced Cancer
Neil Senzer et al.
MOLECULAR THERAPY (2012)
BRCA1 and BRCA2: different roles in a common pathway of genome protection
Rohini Roy et al.
NATURE REVIEWS CANCER (2012)
Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer
Shiyu Zhang et al.
GYNECOLOGIC ONCOLOGY (2011)
Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
Barbara Norquist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
Anand G. Patel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer
Sandhya Pruthi et al.
MAYO CLINIC PROCEEDINGS (2010)
PALB2 Functionally Connects the Breast Cancer Susceptibility Proteins BRCA1 and BRCA2
Fan Zhang et al.
MOLECULAR CANCER RESEARCH (2009)
Autophagy: from basic science to clinical application
J. Van Limbergen et al.
MUCOSAL IMMUNOLOGY (2009)
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance
Elizabeth M. Swisher et al.
CANCER RESEARCH (2008)
Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair
Longchuan Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
BRCAness Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With BRCA1 and BRCA2 Mutations
David S. P. Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites
Jean-Francois Haince et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Removal of BRCA1/CtIP/ZBRK1 repressor complex on ANG1 promoter leads to accelerated mammary tumor growth contributed by prominent vasculature
Saori Furuta et al.
CANCER CELL (2006)
BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions
Ronit I. Yarden et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Hallmarks of 'BRCAness' in sporadic cancers
N Turner et al.
NATURE REVIEWS CANCER (2004)
Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells
H Kawai et al.
ONCOGENE (2002)
Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1
L Zheng et al.
MOLECULAR CELL (2000)
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors
M Esteller et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
